

# MS patients at a greater risk of cancer, new study suggests

*New results of a 65-year follow-up study of patients with Multiple Sclerosis (MS) suggest that patients may have a greater overall risk of developing cancer.*

OSLO, NORWAY, June 28, 2019 /EINPresswire.com/ -- Presented today at the 5th European Academy of Neurology (EAN) Congress in Oslo, Norway, the Norwegian study also indicated an increased risk of developing haematological cancers in non-MS siblings of MS patients, compared with both MS patients and the general population.



5th Congress of the European Academy of Neurology

Cancer type □ Cancer risk among MS patients compared to the non-MS population

Respiratory cancer □ 66% increase in risk  
 Central nervous system (CNS) □ 52% increase in risk

Urinary cancer □ 51% increase in risk

Overall cancer □ 14% increase in risk



This research outlines the need for greater awareness of cancer risk among MS patients, which should lead to shortened cancer diagnosis and more effective therapy in order to improve outcomes."

*Dr Nina Grytten*

Table 1 – increase in cancer risk in MS patients compared to the non-MS population

This long-term analysis was based on patient records from 6,883 MS patients born between 1930–1979, who were registered with various Norwegian MS and Cancer Registries, and prevalence studies from Norway. The analysis also included data from 8,918 siblings without MS, and 37,919 non-MS individuals.

"This study is the first to compare cancer risk in MS with non-affected siblings of MS patients. The risk assessment between these two groups is extremely interesting because they share the same genetics and environmental conditions," noted Dr Nina Grytten, lead researcher of the study, from Haukeland University Hospital, Bergen, who presented the results at the EAN congress.

"Previous clinical studies of cancer risk in MS patients in various countries have shown inconsistent findings, so further research is needed to help improve our understanding in this area," stated Dr Grytten. "This research outlines the need for greater awareness of cancer risk among MS patients, which should lead to shortened cancer diagnosis and more effective therapy

in order to improve outcomes and survival.”

“Additional research could also identify the possible connections between haematological cancer and MS and new ways in which we could manage these conditions”, she added.

Multiple sclerosis is a lifelong disease that affects the central nervous system, especially the brain, spinal cord and optic nerves. It can lead to a wide range of symptoms, including problems with vision, arm or leg movement, sensation or balance. MS is one of the most common causes of disability in younger adults<sup>8</sup>, and people with MS have on average 7 years shorter longevity.

Haematological cancer is a type of blood cancer that includes myeloma, lymphoma and leukaemia. There are many different types of haematological cancers, which can affect the blood, bone marrow and lymph nodes in the body. According to Dr. Grytten, the results of the investigation might suggest that MS and haematological cancer could share a common etiology, which can be important for future treatment of MS and prevention of both diseases.

ENDS

Notes to Editors:

Press Enquiries:

For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at [press@ean.org](mailto:press@ean.org) or call +44 (0) 7732 499170.

About the Expert:

Dr Nina Grytten is from Haukeland University Hospital, Bergen, Norway.

EAN – The Home of Neurology:

The European Academy of Neurology (EAN) is Europe’s home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. This year, EAN celebrates its fifth year of fostering excellence in European neurology and will bring together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe.

In Oslo, Norway, from June 29 to July 2, there will be an exchange of knowledge and promotion of best practice, with a focus on the main theme of neuroinflammation. The EAN Congress will also cover all neurological diseases and disorders, including the big 7: epilepsy, stroke, headache, multiple sclerosis, dementia, movement disorders, neuromuscular disorders.

References:

1. Cancer risk in multiple sclerosis patients, siblings, and healthy controls: a prospective, longitudinal cohort study, presented at the 5th European Academy of Neurology (EAN) Congress in Oslo, Norway.
2. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. *Mult Scler*. 2015 Mar; 21(3): 294–304.
3. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. *Int J Cancer* 2006; 118: 979–984.
4. Söderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. *Eur J Cancer*. 2006; 42: 3028–3033.
5. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple

- sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. *Mult Scler* 2004; 10: 575–581.
6. Goldacre MJ, Seagroatt V, Yeates D, et al. Skin cancer in people with multiple sclerosis: a record linkage study. *J Epidemiol Community Health* 2004; 58: 142–144.
  7. Lebrun C, Vermersch P, Brassat D, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. *J Neurol* 2011; 258: 1304–1311.
  8. NHS. Multiple Sclerosis Overview. <https://www.nhs.uk/conditions/multiple-sclerosis/>. Accessed June 2019).
  9. Lunde HMB, Assmus J, Myhr KM, Bo L and Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. *Journal of neurology, neurosurgery, and psychiatry*. 2017; 88: 621-5
  10. National Cancer Institute. Hematologic Cancer: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hematologic-cancer>. (Accessed June 2019).

Luke Paskins  
European Academy of Neurology (EAN)  
+44 7732 499170  
[email us here](#)  
Visit us on social media:  
[Facebook](#)  
[Twitter](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.